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*S Supporting Information
ABSTRACT: The surface of proteins is heterogeneous with sophisticated but
precise hydrophobic and hydrophilic patches, which is essential for their diverse
biological functions. To emulate such distinct surface patterns on macromolecules, we
used rigid spherical synthetic dendrimers (polyphenylene dendrimers) to provide
controlled amphiphilic surface patches with molecular precision. We identiﬁed an
optimal spatial arrangement of these patches on certain dendrimers that enabled their
interaction with human adenovirus 5 (Ad5). Patchy dendrimers bound to the surface
of Ad5 formed a synthetic polymer corona that greatly altered various host
interactions of Ad5 as well as in vivo distribution. The dendrimer corona (1)
improved the ability of Ad5-derived gene transfer vectors to transduce cells deﬁcient
for the primary Ad5 cell membrane receptor and (2) modulated the binding of Ad5 to
blood coagulation factor X, one of the most critical virus−host interactions in the bloodstream. It signiﬁcantly enhanced the transduction eﬃciency
of Ad5 while also protecting it from neutralization by natural antibodies and the complement system in human whole blood. Ad5 with a synthetic
dendrimer corona revealed profoundly altered in vivo distribution, improved transduction of heart, and dampened vector sequestration by liver and
spleen. We propose the design of bioactive polymers that bind protein surfaces solely based on their amphiphilic surface patches and protect
against a naturally occurring protein corona, which is highly attractive to improve Ad5-based in vivo gene therapy applications.
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Only recently, it has been discovered that the proteincorona largely determines the fate of nanoparticles inthe bloodstream in vivo.1−5 Unlike highly speciﬁc
ligand−receptor recognition, protein corona formation on
nanoparticle surfaces mainly depends on multiple weak
molecular binding events.4 Protein surfaces are not homoge-
neous but provide deﬁned amphiphilic patterns. Although the
role of such amphiphilic surface patches in cell biology is still
barely understood, it has been found essential for their cellular
distribution and various interactions with, for example, other
proteins, membranes, and carbohydrates.6 In consequence,
molecular recognition concepts have been proposed such as the
corona phase model based on folded heteropolymers con-
strained at a single-walled nanotube surface,7 which indicate that
slight polarity diﬀerences could induce large diﬀerences in
molecular biorecognition. The importance of amphiphilic
patches has been previously demonstrated in a synthetic
model, where gold nanoparticles have been prepared with
alternating hydrophobic and hydrophilic segments; these
nanoparticles penetrated cellular membranes more eﬃciently
than particles with the same functional groups homogeneously
distributed on the surface.8 Therefore, we hypothesized that by
engineering speciﬁc amphiphilic patches, one could control
biomolecule recognition and even engineer a protein-like corona
by synthetic macromolecules.
In nature, viruses are among the most intelligent and eﬃcient
nanotransporters. Their enormous eﬃciency not only depends
on their highly speciﬁc receptor binding, but they can also utilize
blood plasma proteins as shielding corona to enhance their
stability and evade the immune system.9 Speciﬁc binding of
blood plasma proteins is predetermined by the surface of the
virus capsid. For instance, blood coagulation factor X (FX) binds
to the surface of adenovirus type 5 (Ad5) forming a protein
corona that shields the viruses from attack by natural antibodies
and complement,9 which also signiﬁcantly enhances their liver
transduction eﬃciency.10,11 In clinical trials, Ad5 is the most
frequently used gene transfer vector to date12 by providing high
transduction eﬃciency in both dividing and nondividing cells
and accommodating large transgene cassettes.13 However, the
clinical applicability of Ad5-based vectors is severely limited by
this native protein corona formation9,10,14 since the absorbed
proteins dictate whether the vector can transduce certain cells in
vivo and frequently lead to mistargeting and acute toxicity.15 For
example, the FX in the protein corona triggers highly eﬃcient
sequestration of Ad vector particles in the liver,10,11 which is a
major limitation in Ad5-based gene therapy. In addition, while
Ad5 in vitro employs the coxsackie−adenovirus cell surface
receptor (CAR) and α(v)β3/5 integrins to infect cells, the
primary receptor CAR is often not available on target tissue in
vivo,16 and tumor cells are often refractory to transduction by
Ad5.17 Therefore, it would be a signiﬁcant advancement for Ad-
based gene therapy if one could engineer an artiﬁcial protein-like
corona that replaces the natural protein corona, which should
shield the vector from neutralizing antibodies and ultimately
engineer virus tropism for therapeutic applications.
Our goal was to mimic the complex amphiphilic patterns like
the surface topology of proteins by shape-persistent poly-
phenylene dendrimers (PPDs) to ultimately control biorecog-
nition of Ad5. PPDs were prepared, providing alternating
negatively charged sulfonic acid and hydrophobic n-propyl
groups (e.g., amphiphilic groups) on their surfaces,18,19 and we
have identiﬁed PPD3 (see Scheme 1) to provide an optimal
amphiphilic surface texture for Ad5 vector binding. PPD3 forms
a protein-like corona on Ad5 and alters Ad5 biorecognition and
Scheme 1. Synthesized PPDs with Amphiphilic n-Propyl and Sulfonic Acid Surface Patchesa
aVariation of the sizes (1st generation G1-Pr4S4, “PPD1” vs 2nd generation, e.g., G2-Pr8S8 or PPD2), negative charges as well as surface patches.
Visualization of the 3D structure of patchy PPD3 and PPD4.
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pathways for gene transduction. We could demonstrate
enhanced vector transduction into low CAR cells, protecting
Ad5 from FX binding and plasma neutralization, and alter the in
vivo tissue distribution of Ad5. Our results are of great relevance
to improve in vivo gene therapy by synthetic polymers, providing
precise amphiphilic surface patterns. We further envision that
our concept could be utilized to create nanoparticle therapeutics
with tailored amphiphilic surface patterns that serve as artiﬁcial
protein corona to control the in vivo distribution of nano-
particles, which represents a holey grail in nanomedicine.
RESULTS AND DISCUSSION
Dendrimers with Precise Amphiphilic Surface
Patches. In cell biochemistry, sulfonic acid groups are only
present in certain carbohydrates such as heparin. Inspired by
heparin sulfate−glycosaminoglycans, which are observed in
blood and undergo multiple protein−protein interactions, we
have synthesized PPDs with surface-exposed sulfonic acid
surface groups. In contrast to carboxylic acids, sulfonic acid
groups are negatively charged independent of the pH (within the
biologically relevant range). As lipophilic residues, propyl chains
were selected due to their performance in a previous in vitro
Figure 1. PPD3 and Ad5 formed complexes with increased transduction eﬃciency onCHO and SKOV-3 cells. (a) Illustration of PPDbinding to
Ad5 and transduction. (b) Fluorescence microscopy images of EGFP expression in CAR-negative CHO-K1 cells. PPD3 signiﬁcantly enhanced
Ad5 uptake and EGFP expression in comparison to other PPDs. (c) Flow cytometric quantiﬁcation of Ad5-mediated EGFP expression in CAR-
negative CHO-K1 and SKOV-3 cells after incubation with PPD1, PPD2, PPD3, and PPD4; MFI stands for mean ﬂuorescence intensity as
absolute values. Transduction was performed with 100 pMOI (particle multiplicity of infection). (d) Flow cytometric quantiﬁcation of Ad5-
mediated EGFP expression in SKOV-3 cell with diﬀerent pMOI of Ad5 (n = 3). (e) TEM images (scale 200 nm) of Ad5 before and after
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screening that analyzed the inﬂuence of various nonpolar
substituents (i.e., phenyl, propyl, isopropyl, butyl, and hexyl
chains) on the cell uptake and toxicity of PPDs.20 1,3,6,8-
Tetraethynylpyrene served as the dendrimer core so that the
blue emission of pyrene could be used as a ﬂuorescence probe to
enable monitoring of the macromolecules via ﬂuorescence
microscopy. PPDs with diﬀerent but precisely established
numbers and orientations of the sulfonic acid/n-propyl surface
groups were synthesized by reacting the core with functionalized
cyclopentadienone building blocks in Diels−Alder cyclo-
additions. Detailed characterization of each sample is also
given in the Supporting Information Section 2 (Scheme 1).21
We then considered the impact of the size (ﬁrst vs second
generation), surface-charge density (PPD2 vs PPD3), and
signiﬁcance of the n-propyl groups (PPD3 vs PPD4) on the
interactions between the “patched” surface dendrimers and Ad5.
In the following sections, we describe the formation of PPD3/
Ad5 complexes and their transduction pathways by a
combination of biological and physicochemical methods. The
key concern is to alter the surface topology of Ad5 by dendrimer
binding to ultimately control and improve critical interactions
with plasma proteins and cells.
PPD3/Ad5 Complexes with Improved Transduction
Eﬃciency. PPD1 to PPD4 were mixed with Ad5 at a desired
ratio in PBS buﬀer, and the gene transduction capabilities of Ad5
in the uncoated and complexed form were tested. Replication-
defective Ad5-based vectors harboring a heterologous ex-
pression cassette for the enhanced green ﬂuorescent protein
(EGFP) were used as model system to study transduction of
diﬀerent cell lines (see SI for details, Ad5 mentioned in the
experimental and results sections always refers to this vector).
Vector particles and PPDs were incubated in PBS buﬀer at a
molar ratio of 1:10 000, and the complexes were subsequently
used for transduction. After 24 h post transduction, EGFP was
quantiﬁed by ﬂow cytometry. CHO-K1 (a subclone of Hamster
Chinese ovary noncancer cell line) and SKOV-3 (human
ovarian cancer cell line) cells were selected, which are diﬃcult to
transduce by Ad5 due to low CAR receptor expression. The
corresponding ﬂow cytometry data are depicted in Figure 1c.
From PPD1 to PPD3, with increasing numbers of alternating
sulfonic acid/propyl groups, the transduction enhancement is
increased accordingly with PPD3/Ad5 complexes exhibiting the
highest transduction eﬃciencies, about 20-fold higher than Ad5
control alone. The presence of amphiphilic surface patches was
crucial for bioactivity since PPD4 with similar size and the same
number of acid groups as PPD3, but lacking the n-propyl chains,
revealed almost no increase of transduction eﬃciency for SKOV-
3 cells. The trends seen for diﬀerent dendrimers were also
Figure 2. Transduction by PPD3/Ad5 complexes was independent of the primary Ad5 receptor CAR and the positively charged KKTKmotif in
the ﬁber capsomere. (a) In the presence of FCS, the transduction of SKOV-3 cells by PPD3/Ad5 complexes was increased (blue line) compared
to the absence of FCS (red line) over a broad range of diﬀerent PPD3/Ad5 ratios. Transduction of the human nonsmall cell lung carcinoma line
A549 was not increased by PPD3/Ad5 complexes (dashed line). Transduction was performed with 1000 pMOI for all PPD3/Ad5 ratios. The
relative MFI value calculated from transduction by Ad5 only is shown. (b) Illustration of the diﬀerence in cell uptake with PPD3/Ad5 and
uncoated Ad5. PPD3/Ad5 uptake into CAR negative cells independent fromCAR receptor, whereas uncoated Ad5 could not. For CAR positive
cells, PPD3/Ad5 might still have utilized the CAR-binding pathway, thus resulting in the same transduction eﬃciency as uncoated Ad5. (c)
Depiction of native Ad5 with positively charged KKTKmotif in the ﬁber, binding CAR as primary receptor and recombinant Ad5/F41s without
the positively charged KKTK motif in the ﬁber that does not bind CAR. (d) Transduction assay with Ad5/F41s and PPD3. Despite a lack of
CAR binding, the KKTK motif PPD3/Ad5/F41s complexes revealed signiﬁcantly enhanced transduction eﬃciency, which indicated the
independence of both CAR and KKTK. ∗∗ represents p-value ≤ 0.01, ∗∗∗ represents p-value ≤ 0.001.
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directly visualized by ﬂuorescence microscopy (Figure 1b and
Figure S3). With increasing virus concentrations (particle
multiplicity of infection = physical particles per cell, pMOI)
from 1000 pMOI to 5000 pMOI, the transduction enhancement
with PPD3 became even more prominent (>30-fold, Figure 1d).
Clearly, biorecognition of Ad5 could be altered after PPD3
binding to the virus surface, and both the ratio of the amphiphilic
groups (sulfonic acid and n-propyl) and their surface density on
PPDs are essential for their interactions with Ad5.
This signiﬁcant binding of PPD3 to Ad5 was therefore studied
further by light scattering and electron microscopy (Figure 1e
and Table S1). By increasing the ratio of PPD3 to Ad5, the
particle sizes of formed complexes increased from 108 ± 11 nm
(Ad5) up to about 729 ± 87 nm for PPD3/Ad5 (1000:1 ratio)
(Table S1) but maintained low polydispersity index (PDI)
below 0.2. In contrast, PPD4 with the same number of sulfonic
acid groups as PPD3, but no n-propyl groups, did not form any
complexes with Ad5 (Table S1) even at very high concentrations
of the dendrimer (10 000:1). The PPD3/Ad5 complexes could
be visualized by transmission electron microscopy (TEM)
(Figure 1e), while, here again, no complexation of PPD4 with
Ad5 was found. Obviously, PPD3 molecules formed a protein-
corona-like structure on Ad5, and the result is in agreement with
the transduction data and supported the assumption that
deﬁned patches of amphiphilic groups (sulfonic acid and n-
propyl) are critical for promoting interactions with Ad5. The
interaction between PPD3 and Ad5 was also detected by
biolayer interferometry (BLI) (Figure S10, Figure S11, and
Table S2). In the BLI experiment, Ad5 particles with high
number of binding sites interact with a ﬂat sensor surface densely
coated with PPD3−dendrimer binding motifs. According to this
method, the calculatedKD (equilibrium dissociation constant) is
as low as 1.27 pM.Most likely, this very strong binding is a result
from multivalent interactions of PPD3 and Ad5, and it does not
reﬂect the binding event of single PPD3 molecules with Ad5.
However, we clearly show that strong interactions occur
between this dendrimer and Ad5.
Enhanced Ad5 Transduction of Cells with Low CAR
Expression. Coxsackie−adenovirus receptor (CAR) is the
main receptor at the cellular membrane that recognizes and
interacts with Ad5.22 Consistently, cells that do not express CAR
(e.g., most tumor cells) can hardly be transduced by Ad5. By
increasing the ratio of PPD3 to Ad5, we observed a saturable
increase in the eﬃciency for Ad5 transduction of SKOV-3 cells
Figure 3. PPD3/Ad5 complexes exhibit increased transduction eﬃciency in human plasma and PPD3 protected FX-binding ablated capsids
from neutralization by the IgM/complement pathway. (a) PPD3/Ad5 complexes were formed and SKOV-3 cells transduced (1000 pMOI) in
the presence or absence of FX at its physiological concentration (8 μg/mL).While FX was expectedly able to signiﬁcantly increase transduction
of SKOV-3 cells, the transduction by PPD3/Ad5 complexes was not enhanced by FX, suggesting that PPD3/Ad5 complexes may not be able to
bind FX. (b) PPD3/Ad5 complexes exhibited increased transduction of largely refractory SKOV-3 cells in the presence of human plasma of an
Ad-naıv̈e donor (1000 pMOI). (c) FX is known to shield Ad5 particles from attack by natural IgM antibodies and complement. A FX-binding
ablated Ad5 vector, a preferable tool for gene transfer and oncolysis due to its signiﬁcantly reduced hepatotropism, did not show enhanced
transduction on SKOV-3 cells (1000 pMOI) but was expectedly neutralized after addition of 5 μL of plasma from an Ad-naıv̈e donor. PPD3/Ad
complexes at a molar excess of 30 000-times were largely resistant to neutralization, indicating that PPD3 can replace FX as a protective shield
against IgM/complement. (d) Comparison of uncoated Ad5, PPD3/Ad5, Ad5ΔFX, and PPD3/Ad5ΔFX for their FX binding and subsequent
neutralizing antibody binding. ∗ represents p-value ≤ 0.05, ∗∗ represents p-value ≤ 0.01.
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with low CAR expression (Figure 2a). In contrast, transduction
of A549 cells with high CAR levels was not inﬂuenced by
increasing concentrations of PPD3 (Figure 2a). Similar
observations were obtained with other high and low CAR cell
lines (Figure S5). These results revealed that the formation of a
PPD3 corona around Ad5 particles could promote an
alternative, yet unknown pathway for Ad5 uptake that
signiﬁcantly improves Ad5 transduction into low CAR cells
(Figure 2b).
Enhanced Transduction in Serum. For in vivo applica-
tions, the impact of serum on the transduction eﬃcacy of the
PPD3/Ad5 complexes is crucial. As demonstrated in Figure 2a,
the presence of fetal calf serum (FCS) did not reduce
transduction eﬃciency of PPD3/Ad5 complexes; instead, we
even observed a signiﬁcantly increased Ad5 transduction
eﬃciency. Increased transduction eﬃcacy has been reported
for DNA-containing lipoplexes23 due to a protein corona coating
of the lipoplexes, which induced diﬀerent cellular uptake
pathways. In addition, it has also been shown that distinct
corona proteins can enhance cellular binding and uptake.24,25
Therefore, to study the interaction between blood proteins and
PPD3, the surface of a literature known model system,
polystyrene nanoparticles (ø = 100 nm) were coated with
PPD3, and the protein corona composition was compared to the
uncoated nanoparticles. Via SDS-PAGE and proteomics
(Figures S12−S14), we could demonstrate that the protein
corona signiﬁcantly changes after the nanoparticles were coated
with PPD3. After incubation with blood serum, a signiﬁcantly
higher amount of vitronectin was bound the PPD3-coated
nanoparticles in comparison to the uncoated ones. Vitronectin is
one example of a corona protein that has been reported to
mediate cellular interactions with cancer cells.26 Further studies
are required to analyze the interaction with serum proteins in
greater detail. In these studies, we could clearly demonstrate that
serum proteins stabilized the PPD3/Ad5 complexes in blood
serum, which is attractive within in vivo applications.
Transduction Independent of Primary Ad5 Receptor
CAR and Positively Charged KKTK Motif in Fiber
Capsomere. Since PPD3 exhibits a net negative charge, we
initially speculated that the interaction of Ad5 and PPD3 could
be of electrostatic nature involving positively charged amino
acids on Ad5. The most prominent positively charged motif at
the Ad5 surface is the KKTK motif located at the ﬁber shaft.27
Therefore, an Ad5 mutant Ad5/F41s lacking the KKTK and
being unable to bind to CAR was investigated (Figure 2c). The
structure of Ad5/F41s is almost identical to Ad5 with only a
deletion of the KKTK motif on the ﬁbers. PPD3/Ad5/F41s
complexes demonstrated very high uptake into SKOV-3 cells, as
indicated by high EGFP expression depicted in Figure 2d. This
result, again, highlighted that compared to Ad5 alone, PPD3
enhanced vector transduction when the CAR pathway was not
available. Also, PPD3 still interacted with Ad5/F41s eﬃciently
despite the absence of the positively charged KKTK. Therefore,
binding between PPD3 and Ad5 most likely occurred at a site
distinct from the ﬁber and did not depend solely on electrostatic
interactions between the negatively charged sulfonic acid groups
of PPD3 and the positively charged KKTK sequence on Ad5.
Instead, the main driving force for the dendrimer interaction
with Ad5 could be the distinct alternating patches of hydrophilic
negative charges and hydrophobic propyl groups of PPD3.
Dendrimer-Coated Ad5 Inhibits Transduction Path-
wayMediated by Blood Coagulation Factor X (FX). Factor
X is a Vitamin K-dependent zymogen of the coagulation cascade.
It is a serine endopeptidase, which is synthesized in the liver.
Trimers of the Ad5 hexon protein bind with nanomolar aﬃnity
to FX, forming 240 FX binding sites per virion.10 Following
intravenous (i.v.) administration of Ad5, viral particles
predominantly accumulate in and transduce the liver in rodent
and nonhuman primate models.28−30 This is a major limitation
for Ad5-mediated gene therapy in humans. In vitro, FX functions
as “bridge receptor” that facilitates attachment of Ad5 to cells.
The γ-carboxyglutamic acid domain of FX binds Ad5, and the
serine protease domain of FX binds cell-surface heparan sulfate
proteoglycan (HSPG).10 Therefore, in agreement with
previously published work,10 addition of FX to cell culture
media could signiﬁcantly enhance the transduction eﬃciency of
Ad5 (Figure 3a). Surprisingly, after mixing of FX with PPD3/
Ad5 complexes, no transduction enhancement was observed
(Figure 3a), which suggested that PPD3 either occupied a
similar binding site on Ad5 as FX or that it was bound to a site
that could aﬀect FX binding. In both cases, FX would be unable
to enhance transduction of PPD3/Ad5 complexes. The results
were corroborated by using superphysiological levels of FX,
which are also unable to improve Ad5 transduction (data not
shown). There is a competition between the PPD3−Ad5 and
FX−Ad5 binding, which indicates that the FX and PPD3 sites
are overlapping. FX is known to interact with the hexon
capsomer; thus, it is very likely that PPD3 also binds to the
hexon proteins. Since FX leads to liver transduction of Ad5 in
vivo, using the PPD3 corona that replaces the FX corona holds
promise for reducing liver toxicity and also to redirect Ad5-based
gene delivery systems to other organs.
PPD3 Corona Protects Ad5 from Plasma Neutraliza-
tion.To solve the challenge of FX-mediated sequestration of Ad
vectors by hepatocytes, a number of strategies have been
proposed including genetic modiﬁcations of the virus capsid to
ablate FX-binding.31 However, Xu et al. have previously
reported that elimination of FX binding enabled Ad
neutralization by natural antibodies and complement. In this
case, the vector was quickly neutralized due to the lack of the
shielding by FX bound to the virus capsid.9 To analyze if PPD3
could shield the viruses from neutralizing natural antibodies and
complement, we incubated the PPD3/Ad5 complex with the
plasma from an Ad naıv̈e human donor prior to transduction.
The eﬃciencies, analyzed on SKOV-3 cells, did not decrease
after plasma incubation (Figure 3b). In addition, we formed
complexes between Ad5 vectors ablated for FX-binding
(Ad5ΔFX) and PPD3 to demonstrate that PPD3 can prevent
plasma neutralization even without FX binding. These
complexes were incubated with human plasma. In the absence
of PPD3, the vectors were completely neutralized by plasma
(Figure 3c), while in the presence of PPD3, infectivity was
preserved to a very large degree: PPD3 not only binds to FX-
binding ablated vectors but also protects them from natural
antibodies and complement (Figure 3d), which is essential for in
vivo applications.
PPD3 Corona Does Not Aﬀect Wild Type Ad5 (wt Ad5)
Activity and Ad5 Replication. The above experiments
utilized a replication-defective adenoviral vector leaving it
unclear whether PPDs would hamper the ability of the virus
to replicate. Any negative impact on virus replication would
disqualify PPD3/Ad5 complexes for oncolytic cancer treatment.
Therefore, we analyzed the potential of PPD3/wt Ad5
complexes to lyse tumor cell lines. Since wt Ad5 lyses tumor
cells, the cytotoxicity assay was used to evaluate the activity of wt
Ad5 (Figure S6). The formation of complexes did, however, not
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inhibit virus replication, but increased lysis of SKOV-3 cells
compared to wt Ad5 alone again made the PPD3/Ad5
complexes suitable tools for oncolytic virotherapy.
Decreased Liver Transduction and Improved Heart
Transduction in Vivo. PPD3/Ad5 complexes were injected
into male C57BL/6J mice at the age of 9 weeks, and
transduction was analyzed in diﬀerent organs 14 days post
injection. We speculated that PPD3/Ad5 complexes would
exhibit reduced liver transduction compared to naked Ad5.
Therefore, the EGFP expression level in liver was initially
assessed by ﬂuorescence imaging of the whole liver tissue
(Figure 4a) to demonstrate Ad5-mediated transduction. In fact,
EGFP expression in liver tissue was reduced by 40% as
supported by immunohistochemical analysis of EGFP in
hepatocytes (Figure 4b). Similar results were also seen by
quantiﬁcation of EGFPDNA in liver using real-time quantitative
PCR (Figure S8). Noteworthy, the liver was found undamaged
in both cases (Figure S9). In addition, EGFP expression was
quantiﬁed in liver, heart, spleen, and lung by Western blot
analysis (Figure 4c,d), which demonstrated decreased trans-
duction of liver and spleen, and lung by about 40% compared to
naked Ad5. Very surprisingly and importantly, PPD3/Ad5
complexes showed increased transduction of heart tissue by
more than 40%.
Therapeutic Potential of Ad5 with Patchy Dendrimer
Corona. PPDs with a deﬁned surface patterning of amphiphilic
groups was able to speciﬁcally bind to the Ad5 surface, altering
the existing surface topology of Ad5 and imparting a synthetic
dendrimer corona providing diﬀerent molecular recognition
features (Figure 5a). In this way, the interaction of Ad5 with (a)
its cellular CAR receptor, (b) plasma proteins, and (c) the
coagulation factor X changes drastically. After PPD3 coating, the
transduction mechanism of the PPD3 coated Ad5 becomes
independent of naturally existing pathways such as CAR and FX,
and it signiﬁcantly prevents the immediate neutralization of the
vector by the innate defense system composed of natural
antibodies and complement. Firm evidence is provided that
upon PPD3 binding, the conventional cellular uptake of Ad5 via
CAR is changed, thus opening a diﬀerent, still unknown
pathway. This furnishes three signiﬁcant advantages providing
potential therapeutic opportunities. First, the complexes can
traﬃc into CAR negative cells, which is not possible for Ad5 and
Ad5/FX. This is highly attractive as many cancer or stem cells do
not express CAR, and therefore, these cells cannot not be
transduced by Ad5. Therefore, PPD3 holds great promise to
widen the therapeutic options of Ad5 as depicted in Figure 5b.
Second, the interaction of Ad5 with serum proteins is altered.
Intravenous delivery of adenovirus vectors requires that Ad5 is
not inactivated in the bloodstream, and serum neutralizing
activity is well documented for Ad5. In the case of Ad5 with
PPD3 corona, serum proteins even boost gene transduction,
which represents an essential feature for in vivo applications.
Third, PPD3 binding has a strong impact on Ad5 interactions
with FX as both PPD3 and FX seem to compete for the same site
at the surface of Ad5, and FX does not aﬀect the transduction
eﬃciency of preformed PPD3 coated Ad5.
Fourth, intravenous (i.v.) administration of Ad5 predom-
inantly leads to accumulation of viral particles in the liver, and
transduction occurs mainly in the liver. Therefore, several
studies have been performed that document the role of blood
coagulation FX in mediating liver gene transfer in vivo and the
mechanism underlying Ad5 hepatocyte transduction10,14,15,32,33
by FX binding to the hexon protein of Ad5 at high aﬃnity (∼2
nM), thus mediating hepatocyte transduction in mice and rats.10
In this way, gene therapy to other organs has been greatly
limited, which can be addressed and improved by Ad5 with
PPD3 corona (Figure 5b). Our in vivo studies proved that the
PPD3 corona signiﬁcantly reduced the Ad5-mediated trans-
duction indicated by EGFP expression in the liver by about 40%
but increase the transduction in the heart by more than 40% in
Figure 4. Decreased liver and improved heart transduction by PPD3/Ad5 complexes in vivo. (a) Fluorescence imaging of the whole mice liver.
(b) Immunohistochemical analysis of liver tissue (10× magniﬁcation). The cell nucleus was stained by hematoxylin indicated in blue; EGFP
was stained by antibodies and DAB (3,3′-diaminobenzidine) as depicted by yellow color. (c) Western blot of EGFP expression in heart, liver,
spleen, and lung. (d) Quantiﬁcation of relative EGFP expression in diﬀerent organs based on Western blot. All data for PPD3/Ad5 are
normalized to the corresponding EGFP expression with naked Ad5 (n = 3). ∗ represents p-value ≤ 0.05, ∗∗ represents p-value ≤ 0.01.
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comparison to naked Ad5. There is, thus, evidence that the
PPD3 corona imparts a diﬀerent biorecognition proﬁle for Ad5,
which alters the Ad5 tropism in vivo.
CONCLUSIONS
Our results demonstrate that rationally synthesized amphiphilic
surface patterns of three-dimensional macromolecules play a
critical role for their biological recognition and interaction with
Ad5. The opportunity to remodel the virus surface by precise
molecular and supramolecular design provides control over
virus−host interactions.
Redirecting Ad5 tropism has been achieved by genetic
engineering of Ad5. However, PPDs with deﬁned amphiphilic
patches provide a versatile strategy to modify the Ad5 surface
and to reengineer Ad5 biodistribution. On the basis of this, one
could further advance Ad5-based gene therapy toward higher
tissue/organ speciﬁcity. Although the reason why the PPD3
complexes target the heart is still unknown, it is envisioned that
by synthesizing PPDs with diﬀerent tissue targeting moieties,
tissue distribution of PPD/Ad5 complexes will be controlled by
rational design. Therefore, we shall attach further tissue speciﬁc
targeting groups to PPD structures to redirect Ad5 transduction
to other organs. This will ultimately regulate the traﬃcking and
cell uptake of viruses in vivo, one of the holey grails in gene
therapy. Moreover, the concept of a bioactive protein-
mimicking polymer corona could allow designing improved
nanoparticle therapeutics to control their in vivo distribution,
which is still one of the major challenges in nanomedicine.
METHODS
Complex Formation of Ad5 and PPD3. Complex formation of
Ad5 and PPD3 was performed in 50 μL of phosphate buﬀered saline
(PBS). This volume contained 5 × 109 Ad5 virus particles (VP) that
resulted in a concentration of 108 Ad5 particles per μL (the
concentration of Ad5 was quantiﬁed by measuring the absorbance at
260 nm and converted to number of particles with the equation:
concentration (VP/mL) = OD260 × 1.1 × 10
12). PPD3 was added in
deﬁned ratios (if not otherwise mentioned, ratio of 1:10 000was used in
the experiments). The volume needed of the PPD 3 stock solution (c =
1 mg/mL, solved in DMSO) was calculated according to the following
formula (N, number of particles; r, ratio between PPD3 and Ad5; M,




N c(PPD 3 stock)A
= × ×
×
Figure 5. Schematic overview of the features of Ad5with PPD3 corona. (a) Comparison of uncoated Ad5 and PPD3/Ad5 complex. CAR binding
site and KKTK motif present on the ﬁber of naked Ad5, while FX and natural antibodies bind to the hexon. PPD3 forms a protein-mimicking
corona on the virus capsid to prevent FX binding and vector neutralization. (b) Summary and visualization of PPD3 binding with Ad5,
highlighting the impact of the PPD3 corona on cell Ad5 uptake processes and in vivo distribution (the ﬁgure is designed by the graphic designer
Weihang Zhao and permission to use is granted).
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This is a calculation example for a PPD3/Ad5 ratio of 1:10 000:
V(PPD3)
5 10 VP 10 000 9766 g/mol







In this sample with a PPD3/Ad5 ratio of 1:10 000, 0.8 μL of the
PPD3 stock solution was added to Ad5 particles and ﬁlled up with PBS
to a volume of 50 μL. Before usage of PPD3, the stock solution was
incubated in the sonicator for∼30min to dissolve assembled molecules
because after some storage time, PPD3molecules tend to self-assemble.
After mixing the solutions, they were incubated for 20 min at room
temperature (RT) and were then used in experiments (Figure S1).
Depending on the experiment settings, the procedure of complex
formation was slightly adjusted as noted in the particular case.
The same procedure was performed with dendrimers PPD1, PPD2,
and PPD3.
Experimental Protocol for Transduction Assay. For trans-
duction assays, 96-well plates were used containing 2 × 104 cells per
well, which were seeded the day before transduction. Cells were
infected with pMOI 1000 unless otherwise speciﬁed and incubated for
24 h (CAR positive cell lines such as A549 cells, Hela cells, andMDCK-
2 cells) or 72 h (CAR negative cell lines such as SKOV-3 cells, CHO-K1
cells, and PTK1 cells) at 37 °C. EGFP positive cells and the overall
mean ﬂuorescence intensity (MFI) of EGFP expression was measured
by ﬂow cytometry.
PPD3/Ad5 Transduction of CAR Positive and CAR Negative
Cells. Hela and MDCK-2 cells were maintained in MEM (minimum
essential medium) (Gibco) supplemented with 10% heat inactivated
FCS, 1% L-glutamine, and 1% penicillin/streptomycin. CHO-K1 cells
were maintained in F-12 Nut Mix (HAM) 1X (Gibco) supplemented
with 10% heat inactivated FCS and 1% penicillin/streptomycin. PTK1
cells were maintained in DMEM supplemented with 10% heat
inactivated FCS, 1% glutamine, and 1% penicillin/streptomycin. All
the cells were maintained at 37 °C under 5% CO2. Then 50 μL of
dendrimers and Ad5 solutions were left to equilibrate for 1 h at 37 °C
and then added to 1 mL of medium in a 12-well ﬂat bottom plate
containing 105 cells (MOI = 10−100) for 24−48 h at 37 °C with
medium supplemented with 2% of FCS. The same experimental
conditions were used in other cell lines. The cells were harvested 24−48
h post-transduction, ﬁxed in 1% paraformaldehyde, stored at 4 °C in
PBS, and protected from light. The fraction of infected cells was
quantiﬁed by ﬂow cytometry, which measured GFP signal of infected
cells. The sample acquisitions were performed with FACSCalibur (BD
Biosciences; USA), and 10 000 events were acquired for each sample.
Untreated cells were set as negative control. Each experiment was
performed in triplicate, and the data were analyzed from two
independent experiments.
Animal Experiment and Bioluminescence Imaging. All animal
studies were performed in compliance with protocols that had been
approved by the Hubei Provincial Animal Care and Use Committee
and the experimental guidelines of the Animal Experimentation Ethics
Committee of Huazhong University of Science and Technology. Male
C57BL/6J mice (purchased from China Three Gorges University) at
the age of 9 weeks were used for in vivo experiments. All mice were
housed in a speciﬁc pathogen-free facility. All mouse experiments were
performed in compliance with institutional guidelines and according to
the protocol approved by the Institutional Animal Care and Use
Committee of Huazhong University of Science and Technology. The
mice were divided into three groups: control group (3 mice), Ad5
group (6 mice), and Ad5+PPD3 group (6 mice). Ad5 (2 × 1010 VP) or
Ad5 incubation with PPD3 (Ad5/PPD3 = 1:10 000, after 20 min) in
200 μL of PBS were administered via tail vein injection. After 2 weeks,
all animals were killed. Then the hearts, livers, spleens, lungs, kidneys,
and brains were harvested, and EGFP expression in the organs was
visualized by bioluminescence imaging at 488 nm/507 nm (excitation/
emission). After that, half of the organs were cryopreserved at −80 °C,
and half were ﬁxed with ﬁxative (4% formaldehyde, 50% ethyl alcohol,
2% acetic acid).
Western Blot Assay. All organs were ground, and whole proteins
were extracted with lysis buﬀer (50 mM HEPES, pH 7.4, containing
150 mM NaCl, 1% Triton X-100, 0.4% SDS, protease inhibitor
cocktail). Protein concentrations were determined by the bicinchoninic
acid (BCA) protein assay kit. Samples were heated to 100 °C for 10min
in loading buﬀer with SDS and β-mercaptoethanol, run on 12% SDS-
PAGE gels in electrophoresis buﬀer (25 mmol/L Tris, 250 mmol/L
glycine, 0.1% SDS), and transferred to PVDF membranes. All blots
were blocked in 5% skim milk in TBST (100 mM Tris−HCl pH 7.5,
150 mM NaCl, 0.1% Tween20) at room temperature for 1 h.
Membranes were probed with rabbit anti-EGFP, anti-GAPDH, or anti-
β-actin (primary antibodies were used at a dilution of 1:4000 in 5%
bovine serum albumin (BSA)−TBST). The HRP-linked secondary
antibody was diluted 1:2000 in 5%milk−TBST and incubation at room
temperature for 1 h. The blots were visualized using an ECL detection
system.
Immunohistochemistry. Organs were ﬁxed with formaldehyde
and embedded in paraﬃn. For immunohistochemistry, thin sections of
the embedded tissues were then blocked with 5% BSA for 2 h at room
temperature and incubated with anti-EGFP (1:200) at 4 °C overnight.
After washing for 15 min, the sections were incubated with biotin-
conjugated secondary antibody for 30 min and further incubated with a
solution of DAB. The sections were then dehydrated in ascending
grades of ethyl alcohol, cleared with xylene, and covered with a
coverslip.
Statistical Analysis. For statistical evaluation of the data, Microsoft
Oﬃce Excel was used. The analysis included calculation of the mean
value and the standard deviation. To compare, for example, diﬀerent
cell lines, relative values were computed. To analyze the data’s statistical
signiﬁcance, p-values were calculated with the TTEST-function
(student’s t test) of Excel. P-values ≤ 0.05 were regarded as signiﬁcant
and labeled in graphs with one asterisk (∗). Data points with two
asterisks indicated p-values ≤ 0.01 and three asterisks p-values ≤ 0.001.
P-values of data points, which were regarded as signiﬁcant, were also
provided in brackets in the text where these data were analyzed and
were marked with “p”. Samples of all experiments were analyzed in
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